Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease

被引：25
作者：
Knopman, David S. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
来源：
COGNITIVE AND BEHAVIORAL NEUROLOGY | 2008年 / 21卷 / 04期
关键词：
Alzheimer disease; clinical trials; cholinesterase inhibitors;
D O I：
10.1097/WNN.0b013e318190cf75
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old, Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.
引用
收藏
页码：197 / 201
页数：5
相关论文
共 42 条
[21]  
Leber P, 1997, ALZ DIS ASSOC DIS, V11, pS37
[22]  
LEBER P, 1990, 1 DRAFT
[23]  
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
[24]  
Mohs RC, 1997, ALZ DIS ASSOC DIS, V11, pS13
[25]   A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [J].
Mohs, RC ;
Doody, RS ;
Morris, JC ;
Ieni, JR ;
Rogers, SL ;
Perdomo, CA ;
Pratt, RD .
NEUROLOGY, 2001, 57 (03) :481-488
[26]   THE CLINICAL DEMENTIA RATING (CDR) - CURRENT VERSION AND SCORING RULES [J].
MORRIS, JC .
NEUROLOGY, 1993, 43 (11) :2412-2414
[27]   Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial [J].
Mulnard, RI ;
Cotman, CW ;
Kawas, C ;
van Dyck, CH ;
Sano, H ;
Doody, R ;
Koss, E ;
Pfeiffer, E ;
Jin, S ;
Gamst, A ;
Grundman, M ;
Thomas, R ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08) :1007-1015
[28]   Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial [J].
Peskind, Elaine R. ;
Potkin, Steven G. ;
Pomara, Nunzio ;
Ott, Brian R. ;
Graham, Stephen M. ;
Olin, Jason T. ;
McDonald, Scott .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (08) :704-715
[29]   MEASUREMENT OF FUNCTIONAL ACTIVITIES IN OLDER ADULTS IN THE COMMUNITY [J].
PFEFFER, RI ;
KUROSAKI, TT ;
HARRAH, CH ;
CHANCE, JM ;
FILOS, S .
JOURNALS OF GERONTOLOGY, 1982, 37 (03) :323-329
[30]   Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension [J].
Raskind, MA ;
Peskind, ER ;
Wessel, T ;
Yuan, W .
NEUROLOGY, 2000, 54 (12) :2261-2268
12345